No products in the cart
Fragment 176-191 & CJC-1295 & Ipamorelin Blend (12mg)
Fragment 176-191 & CJC-1295 & Ipamorelin Blend are Synthesized and Lyophilized in the USA.
Discount per Quantity
|Quantity||5 - 9||10 +|
FREE - 30ml bottle of bacteriostatic water
(Required for reconstitution)
FREE - USPS priority shipping
HGH Fragment 176-191 houses the primary proposed ‘lipolytic fragment’ of the growth hormone (HGH) and it potentially targets the beta-3 adrenergic receptors (ADRB3), which may facilitate its suggested weight-loss potential. This peptide is proposed to amplify fat burning in adipose tissue cells and stimulate ‘thermogenesis’ in skeletal muscle cells via these receptors.
CJC-1295, also termed DAC: GRF, is an apparently enhanced version of GHRH (1-29) crafted to potentially optimize its pharmacokinetics. It is posited to elevate Growth Hormone and Insulin-Like Growth Factor 1 (IGF-1) levels. Research suggests it may boost Growth Hormone production between 200-1000%. Furthermore, CJC-1295 is believed to increase plasma IGF-I concentrations by 1.5- to 3-fold. This surge in growth hormone levels is purported to be sustained for about a week, suggesting a long-lasting CJC-1295 action.
Ipamorelin, a five-amino-acid chain, is identified as a Growth Hormone Secretagogue (GSH). It’s posited to function similarly to Growth Hormone Releasing Peptides (GHRPs) and to apparently emulate the natural hunger hormone, ghrelin, particularly its potential to stimulate the release of HGH from pituitary cells. Ipamorelin has been studied for its potential in boosting vitality and health, with possible anti-aging effects on skin cells and other tissues. A potentially notable feature of Ipamorelin research is its selectivity and its reported negligible influence on the secretion of other pituitary hormones like cortisol, prolactin, and aldosterone.
Fragment 176-191 Specifications
Molecular Formula : C78H125N23O23S2
Molecular Weight : 1817.1 g/mol
Sequence : Tyr-Leu-Arg-Ile-Val-Gin-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
CAS Number : 66004-57-7
Reconstitution : Required
Molecular Formula: C152H252N44O42
Molecular Weight: 3647.954 g/mol
PubChem: CID 56841945
Other: DOES NOT CONTAIN DAC
Molecular Formula: C38H49N9O5
Molecular Weight: 711.85 g/mol
PubChem: CID 9831659
CAS Number: 170851-70-4
Potential of Fragment 176-191 & CJC-1295 & Ipamorelin Peptide Blend
Studies in animal models have suggested the efficacy of Fragment 176-191, a short stretch of growth hormone (HGH), in promoting fat mobilization and triggering a metabolic shift towards the perpetuation of lean body mass. It appears to further lack the proposed implications sometimes seen with hGH supplementation, such as long-bone growth, reduced sensitivity to insulin, and edema. It has been reported by researchers to potentially boost natural immune system functioning, metabolic processes, and promote cartilage regeneration. The peptide fragment has also been observed to promote GH secretion by regulating physiological processes involved in GH synthesis. The scientifically-studied potential of Fragment 176-191 include effective fat burning via increased lipolysis and decreased lipogenesis and adequate energy levels. It does not appear to significantly alter glucose tolerance, insulin sensitivity, or IGF-1 levels, though more research is needed to further support these hypotheses.
CJC-1295 is another synthetic GH releasing hormone. It appears to promote the production of GH and can be used as a potential stimulation for GH synthesis. Researchers have commented that the peptide appears to cause “increases in mean plasma GH concentrations by 2- to 10-fold […] and in mean plasma IGF-I concentrations by 1.5- to 3-fold…” CJC-1295 has been primarily researched for its potential in mitigating actions frequently associated with aging. CJC-1295 may improve basal as well as highest physiological levels of GH. It may further increase the availability of free GH in plasma. Numerous studies have suggested that CJC-1295 may maintain normal growth and body mass. For example, research involving murine specimens with a GHRH gene deletion (known as GHRHKO) noted that CJC-1295 might exhibit tissue-specific effects. When these GHRHKO specimens were exposed to CJC-1295, they seemed to maintain standard weight and length, compared to control models which failed to achieve normal weight and length. Moreover, both the relative lean mass and the subcutaneous fat mass remained at control levels across all peptide-associated groups, indicating that the CJC-1295 may potentially benefit muscle and bone tissues without stimulating an increased adiposity. Another standout observation by the scientists was a potential rise in total pituitary RNA and GH mRNA due to CJC-1295, suggesting a possible increase in somatotroph cells – the pituitary gland cells believed to produce growth hormone. This cell increase was further corroborated by immunohistochemistry visuals. By potentially regulating growth hormone production, CJC-1295 may possibly provide positive action against naturally occurring processes associated with organism aging, attributed to decreased growth hormone production.
Ipamorelin is a peptide that research studies indicate may function as an agonist for the GH secretagogue receptor. It has been studied in combination with Fragment 176-191 and CJ-1295 for the potential to synergistically enhance the secretion of GH and maximize its physiological level. Animal studies have suggested Ipamorelin to be beneficial in regulating insulin and bone mineralization. The researchers reported that it “stimulates insulin release through the calcium channel and the adrenergic receptor pathways.” Interestingly, it appears to mediate an immediate short-term response, causing a rapid GH release. CJC-1295, by contrast, appears to exercise a long-term influence by enhancing GH secretion over an extended duration and helps maintain standard physiological secretion patterns of GH. Having a reported half-life of just 2 hours, Ipamorelin may be cleared more rapidly. Keeping in view the pharmacokinetics of the two peptides, researchers have studied them in combination to ensure a rapid response (attributed to Ipamorelin) and long-lasting action (owing to CJC-1295).
Ipamorelin may also have potential action outside GH-producing cells, such as affecting the function of osteoblasts in bone. In murine research scientists investigated the potential of either Ipamorelin or a placebo on bone tissue. Bone mineral density (BMD) changes were tracked in real-time using dual X-ray absorptiometry (DXA). Post-research, the femurs were examined with mid-diaphyseal peripheral quantitative computed tomography (pQCT). The preliminary results possibly indicated a weight increase and a potential rise in tibial and vertebral bone mineral content (BMC) with Ipamorelin, as observed by DXA, compared to the placebo. However, when accounting for weight, no significant BMC shift was observed. There was a possible increase in tibial BMD (ratio of BMC to area), but overall and vertebral BMDs might have remained consistent. pQCT data possibly suggested the cortical BMC boost could be due to a larger bone cross-section, while the cortical volumetric BMD (bone volume density) might have stayed stable. Both femur and vertebrae sizes could have potentially increased, but their volumetric BMDs seemed unchanged. These findings suggest that the observed BMC increase might potentially be attributed to improved bone size and structure, while the volumetric BMD possibly remained the same.
Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.
- Ferrer-Lorente R, Cabot C, Fernández-López JA, Alemany M. Combined effects of oleoyl-estrone and a beta3-adrenergic agonist (CL316,243) on lipid stores of diet-induced overweight male Wistar rats. Life Sci. 2005 Sep 2;77(16):2051-8. doi: 10.1016/j.lfs.2005.04.008. PMID: 15935402.
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. doi: 10.1210/jc.2005-1536. Epub 2005 Dec 13. PMID: 16352683.
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. doi: 10.1530/eje.0.1390552. PMID: 9849822.
- Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-8. doi: 10.1159/000053183. PMID: 11146367.
- Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001 Dec;142(12):5182-9. doi: 10.1210/endo.142.12.8522. PMID: 11713213.]
- Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1290-4. doi: 10.1152/ajpendo.00201.2006. Epub 2006 Jul 5. PMID: 16822960.
- Van Hout MC, Hearne E. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Subst Use Misuse. 2016 Jan 2;51(1):73-84. doi: 10.3109/10826084.2015.1082595. Epub 2016 Jan 15. PMID: 26771670.
- Adeghate E, Ponery AS. Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuro Endocrinol Lett. 2004 Dec;25(6):403-6. PMID: 15665799.
- Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999 Sep;16(9):1412-6. doi: 10.1023/a:1018955126402. PMID: 10496658
- Svensson J, Lall S, Dickson SL, Bengtsson BA, Rømer J, Ahnfelt-Rønne I, Ohlsson C, Jansson JO. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000 Jun;165(3):569-77. doi: 10.1677/joe.0.1650569. PMID: 10828840.
Dr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson & Johnson and Sanofi.